Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid leukaemia (AML) 1,2 , bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue in numerous cancers [3][4][5] . While clinical trials have reported single-agent activity in advanced haematological malignancies 6 , mechanisms determining the response to BET inhibition remain poorly understood. To identify factors involved in primary and acquired BET resistance in leukaemia, here we perform a chromatin-focused RNAi screen in a sensitive MLL-AF9;Nras G12D -driven AML mouse model, and investigate dynamic transcriptional profiles in sensitive and resistant mouse and human leukaemias. Our screen shows that suppression of the PRC2 complex, contrary to effects in other contexts, promotes BET inhibitor resistance in AML. PRC2 suppression does not directly affect the regulation of Brd4-dependent transcripts, but facilitates the remodelling of regulatory pathways that restore the transcription of key targets such as Myc. Similarly, while BET inhibition triggers acute MYC repression in human leukaemias regardless of their sensitivity, resistant leukaemias are uniformly characterized by their ability to rapidly restore MYC transcription. This process involves the activation and recruitment of WNT signalling components, which compensate for the loss of BRD4 and drive resistance in various cancer models. Dynamic chromatin immunoprecipitation sequencing and self-transcribing active regulatory region sequencing of enhancer profiles reveal that BET-resistant states are characterized by remodelled regulatory landscapes, involving the activation of a focal MYC enhancer that recruits WNT machinery in response to BET inhibition. Together, our results identify and validate WNT signalling as a driver and candidate biomarker of primary and acquired BET resistance in leukaemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.
, bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue in numerous cancers [3] [4] [5] . While clinical trials have reported single-agent activity in advanced haematological malignancies 6 , mechanisms determining the response to BET inhibition remain poorly understood. To identify factors involved in primary and acquired BET resistance in leukaemia, here we perform a chromatin-focused RNAi screen in a sensitive MLL-AF9;Nras G12D -driven AML mouse model, and investigate dynamic transcriptional profiles in sensitive and resistant mouse and human leukaemias. Our screen shows that suppression of the PRC2 complex, contrary to effects in other contexts, promotes BET inhibitor resistance in AML. PRC2 suppression does not directly affect the regulation of Brd4-dependent transcripts, but facilitates the remodelling of regulatory pathways that restore the transcription of key targets such as Myc. Similarly, while BET inhibition triggers acute MYC repression in human leukaemias regardless of their sensitivity, resistant leukaemias are uniformly characterized by their ability to rapidly restore MYC transcription. This process involves the activation and recruitment of WNT signalling components, which compensate for the loss of BRD4 and drive resistance in various cancer models. Dynamic chromatin immunoprecipitation sequencing and self-transcribing active regulatory region sequencing of enhancer profiles reveal that BET-resistant states are characterized by remodelled regulatory landscapes, involving the activation of a focal MYC enhancer that recruits WNT machinery in response to BET inhibition. Together, our results identify and validate WNT signalling as a driver and candidate biomarker of primary and acquired BET resistance in leukaemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.
BRD4 is a chromatin reader that regulates transcription through linking histone acetylation and core components of the transcriptional apparatus 7 . Recent studies suggest that BRD4 regulates distinct gene sets through interacting with context-specific enhancers and transcription factors 8, 9 . However, the mechanisms underlying the wide range of sensitivity to BET inhibition remain elusive, and so far no predictive biomarker has been identified. Towards understanding these mechanisms, we sought to functionally identify chromatin factors that are required for rendering AML cells sensitive to JQ1, a well-known BET inhibitor 10 . To this end, we constructed a microRNA-embedded short hairpin RNA (shRNAmir) library covering 626 chromatin regulators and screened it in the same MLL-AF9;Nras G12D -driven model that led to the identification of BRD4 as a candidate target 1 (Fig. 1a) . Deepsequencing following transduction (T0) and 7 days of selection (T1) identified chromatin-associated dependencies, including Smarca4 and Brd4 as top hits (Extended Data Fig. 1a-c) . To control for unspecific events, we mixed the GFP 1 library population with mCherry 1 control cells, and subsequently treated with DMSO or JQ1. While mCherry 1 cells disappeared over time (Fig. 1b) , GFP 1 cells survived and eventually grew in the presence of 50 nM JQ1 (corresponding to an IC 70 dose; Extended Data Fig. 1d ), indicating that resistance emerged from shRNA-mediated effects. Four shRNAs showed an outstanding enrichment that was consistent between replicates, despite almost 5 weeks of independent culture ( Fig. 1c and Extended Data Fig. 1a , e). These included two shRNAs targeting Suz12, one targeting Psip1, and one previously characterized potent Dnmt3a shRNA 11 . All four shRNAs strongly suppressed their target mRNA (Extended Data Fig. 1f) , and validated to promote JQ1 resistance in single assays ( Fig. 1d and Extended Data Fig. 2a) .
The finding that suppression of Suz12, a component of the PRC2 complex, promotes resistance to JQ1 was surprising in two ways. First, a recent report, based on studies in nerve sheath tumours, has implicated Suz12 deficiency as a condition that increases sensitivity to BET inhibition 12 . Second, several studies (including work from our group) have characterized PRC2 as a requirement in MLL-AF9-driven AML 13, 14 . Notably, the most potent Suz12 shRNA in previous studies (Suz12.1676) did not score in the pooled screen and validated to strongly inhibit proliferation in our model (Fig. 1e) . However, when we added JQ1, Suz12.1676-expressing cells were rapidly enriched, indicating that Suz12 deficiency turns from a detrimental into a favourable condition. Similar effects were observed using potent shRNAs targeting Ezh2 and Eed, two other PRC2 components ( Fig. 1e and Extended Data Fig. 2b ). We also validated this phenomenon using Tet-regulatable RNA interference, where we included a validated Myc shRNA 15 to rule out that resistance is merely a consequence of reduced proliferation (Extended Data Fig. 2c ). Resistant cells generated through Suz12 suppression showed a global loss of H3K27me3 (Fig. 1f) , and were also refractory to the effects of JQ1 in methyl-cellulose assays (Extended Data Fig. 2d ) and in vivo (Fig. 1g) . While recipient mice of Suz12-deficient cells, consistent with previous observations 14 , showed a delayed disease progression, JQ1 had no anti-leukaemic effects in this context (Fig. 1g) . Together, these data demonstrate that loss of Suz12 impairs rather than promotes BET sensitivity in AML, revealing another scenario where PRC2 plays opposing roles in different cancers.
To search for underlying mechanisms, we investigated whether our hits affected the regulation of BRD4-dependent transcripts, and found that the acute response to JQ1 is largely unchanged in the absence of Suz12, Dnmt3a or Psip1 (Fig. 2a) . However, under long-term treatment, 60-80% of JQ1-induced changes reverted and transcription of the key target Myc 1,3 was restored ( To investigate this rebound phenomenon, we focused subsequent analyses on PRC2, a writer of repressive H3K27me3 marks 16 . Based on recent reports showing that BRD4 interacts with WHSC1L1 17 , a writer of H3K36 methylation marks that can recruit PRC2 18 , we wondered whether PRC2 is involved in repressing BRD4 targets following BET inhibition. However, chromatin immunoprecipitation sequencing (ChIP-seq) analysis before and after JQ1 treatment showed no increase in H3K27me3 at Brd4 occupancy sites (Extended Data Fig. 2f, g ), which together with RNA-seq studies suggests that PRC2 does not regulate these genes directly.
Next, we investigated whether the rebound of BRD4 targets is associated with changes in the enhancer landscape. Under long-term JQ1 treatment, resistant cells showed a global loss of enhancer-associated H3K27ac marks, which was reversible upon drug withdrawal (Extended Data Fig. 3a) . At the level of Myc, the loss of H3K27ac ). G418-selected cell populations were mixed and treated with DMSO or 100 nM JQ1 for 4 days followed by 50 nM JQ1 for 22 days. Genomic DNA isolated from T0, T1 and T2 was used to amplify and deep-sequence shRNA guides. b, Relative abundance of mCherry 1 control cells and absolute number of GFP 1 /shRNA-expressing cells in the screen population over time. c, Scatter plot showing the average ratio of normalized reads before (T1) and after 26 days of DMSO-or JQ1 treatment (T2) for all 2,917 shRNAs. d, e, Competitive proliferation assays of MLL-AF9;Nras G12D leukaemia cells expressing the indicated shRNAs. Shown is the relative fraction of GFP target genes through remodelling of regulatory landscapes and pathways. a, Heat map showing RPKM fold change (FC) of 235 response genes in MLL-AF9;Nras G12D leukaemia cells expressing the indicated shRNAs after treatment with DMSO or JQ1 (200 nM) for 2 h or 24 h, and after long-term (LT) JQ1 treatment (50 nM) for 6 weeks. Response genes were defined based on JQ1-induced changes in Ren.713 expressing leukaemia cells (FC .2/,0.5 after 2 h and FC .2/,0.33 after 24 h). Samples are presented according to non-hierarchical clustering; genes are grouped in up-or downregulated targets in Ren.713 control cells, and sorted by their average re-expression in resistant leukaemia. b, Response genes in a were grouped into four categories based on the divergence of their expression in resistant AML compared to AML expressing Ren.713 (see legend of Extended Data Fig. 2e for details) . c, Time course of Tifab and Myc transcript levels in MLL-AF9;Nras G12D leukaemia expressing the indicated shRNAs, relative to untreated cells expressing Ren.713. d, ChIP-seq occupancy profiles of Brd4 and H3K27ac in Myc regulatory regions in sensitive AML cells (wild type and Ren.713) and Suz12.1842-expressing resistant AML cells under long-term treatment with JQ1 (50 nM). The H3K27ac profile in Ren.713 control AML cells is shown on top for the entire region (,2 Mb), together with validated transcript models from the mm10 genome assembly. Additional tracks are zoomed in on the proximal region and a distal region containing an established cluster of enhancers (E1-E5) 19 , as indicated (dotted lines). The y axis reflects the number of normalized cumulative tag counts in each region. e, Schematic of RNA-seq profiling in resistant AML cells generated through expression of three independent shRNAs targeting Suz12 or Ezh2, which are treated as biological triplicates and compared to triplicate control cells. f, Gene set enrichment analysis of expression changes in 22 KEGG signalling pathways in resistant AML cells generated as described in e. Plotted are normalized enrichment scores (NES) against nominal P values; significantly altered gene sets (P , 0.05) are indicated in the graph. 
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was most prominent at a 39 cluster of lineage-specific enhancers known to be required for Myc transcription 19 ( Fig. 2d) . In parallel, we observed a strong focal gain of H3K27ac in the first intron of Pvt1 (a long non-coding RNA 39 of Myc), which was the tenth most prominent of only 119 genomic regions that gained H3K27ac in resistant cells (Fig. 2d and Extended Data Fig. 3b, c) . Together, these findings reveal that BET resistance is associated with profound changes in the enhancer landscape.
To probe regulatory pathways involved in the re-expression of Brd4 targets, we analysed the transcriptomes of sensitive and resistant cells generated using three independent PRC2 shRNAs (Fig. 2e) . Gene set enrichment analysis 20 identified alterations in five major signalling pathways (Fig. 2f) . Almost half of the genes associated with upregulated pathways contain H3K27me3 marks in sensitive cells (Extended Data Fig. 3d-f ), indicating that loss of PRC2 can facilitate their transcriptional activation. The most significant alteration was an upregulation of genes associated with Wnt signalling, which can drive Myc transcription 21 and has important functions in normal and leukaemic stem cells (LSC) 22, 23 . Of note, resistant cells in our model were not enriched for LSC-associated surface markers and expression signatures (Extended Data Fig. 4a-c) , which does not exclude a role of LSC in resistance. Collectively, our findings suggest that loss of PRC2 promotes resistance through facilitating the derepression of compensatory pathways that restore the transcription of critical BRD4 target genes.
Given this complexity, we sought to explore whether any phenomena in our model of acquired resistance are also associated with primary BET resistance. To this end, we determined the JQ1 sensitivity in 246 human cell lines (Extended Data Fig. 5a ), and selected three sensitive and three resistant lines from three cancer subtypes for dynamic transcriptional profiling. While RNA-seq profiles distinguished cancer subtypes as expected, sensitive and resistant contexts could not be differentiated, neither through their steady-state transcriptomes, nor through comparing JQ1-induced changes (Extended Data Fig. 5b, c) . In fact, BET inhibition triggered highly distinct responses regardless of whether MYC is affected, and even cancers of similar tissue and sensitivity profile do not share greater overlaps ( Fig. 3a and Extended Data Fig. 5d-f ). To test whether this heterogeneity is associated with differential functions of JQ1 targets, we used Tet-regulated shRNAmirs to profile BRD2/3/4-dependent transcripts in sensitive and resistant leukaemia cells. In both cases, JQ1-induced changes showed the largest overlap with BRD4-knockdown profiles (Extended Data Fig. 6a-d) , indicating that suppression of BRD4 dominates the effects of BET inhibition in leukaemia.
Despite this heterogeneity, a closer look at the few commonly regulated genes (Extended Data Fig. 6e ) revealed two interesting findings: (1) one of two transcripts commonly induced by JQ1 was HEXIM1, which we found upregulated in all analysed cancers (Extended Data Fig. 6f ), indicating that it could serve as a pharmacodynamic biomarker. (2) Surprisingly, one of three transcripts repressed after 2 h of JQ1 treatment in both sensitive and resistant leukaemias was MYC. In sensitive leukaemias, this repression was durable and led to strong suppression of the MYC protein (Fig. 3b) , while all resistant leukaemias showed a rapid rebound of MYC transcription and, consequently, only minimal protein suppression. Similar effects were observed in a larger panel of haematopoietic cell lines ( Fig. 3c and Extended Data Fig. 6g ), indicating that primary BET resistance is not due to BRD4-independent regulation of critical targets, but driven by compensatory mechanisms that rapidly restore their transcription.
To investigate how this rebound phenomenon is encoded in the enhancer landscape, we performed H3K27ac ChIP-seq, which revealed that resistant K-562 cells contain several H3K27ac peaks around MYC that are missing in sensitive MOLM-13 cells. These include a strong occupancy in the first intron of PVT1 (Fig. 3d) , the same region that gained H3K27ac in our mouse model (Fig. 2d) . To systematically analyse how these putative MYC enhancers change their activity upon BET inhibition, we performed self-transcribing active regulatory region sequencing (STARR-seq; a new method for high-throughput functional enhancer analysis 24 ) using a library covering 3.1 megabase pairs surrounding MYC (Extended Data Fig. 7a ). While the PVT1 element had little activity in DMSO-treated K-562 cells, its enhancer activity strongly increased after 24 h of JQ1 treatment (Fig. 3e) and defined the single strongest gain in the entire region (Fig. 3f) . We confirmed this effect in conventional reporter assays using a minimal MYC promoter (Fig. 3g ) and found that it does not correlate with PVT1 transcription (Extended Data Fig. 7b ), indicating that this element primarily acts as a MYC enhancer. Collectively, our results suggest that the rebound of MYC is driven by a focal enhancer that is formed during acquired resistance and pre-established in primary resistant cells.
To search for regulatory pathways driving primary resistance, we compared steady-state transcriptomes of sensitive and resistant leukaemias. Among only 38 genes consistently upregulated in resistant leukaemias, we identified 17 genes previously implicated as Wnt signalling LETTER RESEARCH targets (Fig. 4a ), which together with findings in our mouse model (Fig. 2f) pointed to Wnt signalling as a candidate driver of BET resistance. From these 17 genes, we selected two well-established Wnt targets, IGF2BP1 25 and TCF4
26
, to test whether they contribute to the resistant state of K-562 cells. Suppression of TCF4 or IGF2BP1 increased the JQ1 sensitivity and diminished transcriptional rebound phenomena in K-562 cells (Fig. 4b, c and Extended Data Fig. 8a ), while overexpression of TCF4 in MOLM-13 cells reduced their sensitivity (Extended Data Fig. 8b, c) .
To investigate whether resistant cells engage Wnt transcriptional machinery following BET inhibition, we performed ChIP assays for TCF7L2, a Wnt-dependent transcription factor known to drive MYC and other Wnt targets in complex with CTNNB1 21 . Following JQ1 treatment, established Wnt target genes showed a marked increase in TCF7L2 binding, which was particularly prominent at the PVT1 element 39 of MYC (Extended Data Fig. 8d ), suggesting that this site acts as a Wnt-dependent MYC enhancer. To test whether Wnt activation drives de novo resistance, we transduced cells of our sensitive AML mouse model with validated shRNAs targeting Apc (Extended Data Fig. 8e, f) , a negative regulator of Wnt signalling, or active mutants of Ctnnb1. While Wnt activation had no or slightly detrimental effects in untreated cells, JQ1 treatment led to a rapid outgrowth of cells expressing two independent Apc shRNAs or Ctnnb1 containing four activating mutations (Ctnnb1.4x) (Fig. 4d, e and Extended Data Fig. 8g ). Single-mutant Ctnnb1 had milder effects, indicating that the degree of BET resistance depends on Wnt activation levels. Ctnnb1.4x also completely blunted the response to JQ1 in vivo, and promoted resistance in two independent leukaemia models (Extended Data Fig. 8h, i) .
After demonstrating that Wnt activation drives resistance in leukaemia, we wondered whether our Wnt expression signature would be more generally associated with BET resistance. Through integrating sensitivity profiles of 246 cell lines with available transcriptome data 27, 28 , we found that expression of this gene set is significantly increased in JQ1-resistant contexts (Extended Data Fig. 9a, b) . As a first step towards probing Wnt as a BET resistance driver in other cancers, we found that suppression of Apc promotes resistance in a mouse model of pancreatic cancer, while treatment with the Wnt inhibitor pyrvinium 29 synergizes with JQ1 in this model and highly resistant ASPC-1 cells (Extended Data Fig. 9c-e) . To probe whether Wnt signalling is associated with BET resistance in primary human leukaemia, we quantified nine Wnt-associated transcripts in sensitive and resistant patient-derived samples (Extended Data Fig. 10a) . Notably, three of these transcripts (that is, TCF4, CCND2 and HOXB4) were significantly overexpressed in resistant samples (Fig. 4f) , while others showed a similar trend (Extended Data Fig. 10b ). To reduce context-specific biases of single markers, we used the three significant transcripts to establish a simple 'resistance index', which strongly correlated with IC 50 values (Extended Data Fig. 10c ) and may provide a first step towards developing a predictive biomarker.
Through integrative profiling and functional genetic analyses in mouse and human leukaemia, our study reveals that BRD4 regulates a remarkably specific and diverse set of target genes. Leukaemia cells, through an adaptation process that is facilitated by inactivation of PRC2, can become resistant to BET inhibition by rewiring the transcriptional regulation of key BRD4 targets such as MYC (Fig. 4g ). Interestingly, a recent study found that in T-lymphoblastic leukaemia MYC transcription can switch from a NOTCH1-dependent to a BRD4-dependent mode following treatment with c-secretase inhibitors 30 . Our study reveals that the BRD4-dependency of MYC can be overcome through engaging a focal enhancer and, together with another report 31 , establishes WNT signalling as a major driver and candidate biomarker of BET resistance in leukaemia. These findings highlight that the heterogeneity and plasticity of transcriptional machinery plays a major role in promoting resistance to chromatintargeted therapies.
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Rel. expression (log) /shRNA 1 cells was followed over time. f, qRT-PCR analysis of TCF4, CCND2 and HOXB4 mRNA levels (relative to GAPDH) in sensitive (n 5 6; IC 50 , 200 nM) and resistant (n 5 6; IC 50 . 500 nM) primary human leukaemia samples (Student's t-test; *P , 0.05; **P , 0.01). g, Model of transcriptional plasticity as a driver of primary and acquired BET resistance. 
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Plasmids. The shRNA library used in the screen was cloned into pLMN (pMSCVmiR30-PGK-NeoR-IRES-GFP) 15 . The same vector was used for validation of primary hits and PRC2 core complex partners. Additional validation studies for Suz12 were performed using pRT3GEN-mir30 (pSIN-TRE3G-turboGFP-miR30-PGK-NeoR) or pLENC (pMSCV-miRE-PGK-NeoR-IRES-mCherry) 11 . shRNAs targeting Apc were cloned into pLMPC (pMSCV-miRE-PGK-PuroR-IRESmCherry). A Ctnnb1 cDNA harbouring four activating mutations (S33A, S37A, T41A, S45A; Ctnnb1.4x) was obtained from Addgene (#24312) and cloned into pMSCV-IRES-mCherry. Ctnnb1 harbouring a single mutation (S45P; Ctnnb1.1x) was cloned into pMSCV-IRES-GFP. shRNAs targeting TCF4 and IGF2BP1 were cloned into pRT3GEN (pSIN-TRE3G-turboGFP-miRE-PGK-NeoR) 11 , and the TCF4 cDNA was cloned into pMSCV-PGK-NeoR-IRES-GFP. Antibodies. The following antibodies were used: Suz12 (39357, Active Motif), histone H3K27me3 (39155, Active Motif; 07-449, Millipore), histone H3K36me3 (Ab9050, Abcam), histone H3K27ac (ab4729, Abcam), histone H3 (61277, Active Motif), MYC (56058, Cell Signaling), TCF4 (ab130014, Abcam), IGF2BP1 (RN001M, MBL), TCF7L2 (sc-8631, Santa Cruz), BRD4 (A301-985A1002, Bethyl), BRD3 (A302-583A, Bethyl), BRD2 (A302-368A, Bethyl), APC (MABC202, Millipore) and b-actin (A3854, Sigma-Aldrich and ab49900, Abcam). Secondary antibodies were anti-mouse (926-32210, LI-COR), anti-rabbit (926-32211, LI-COR) and anti-goat (926-32214, LI-COR). Antibodies used for FACS were: PE anti-mouse CD117/c-Kit (Biolegend, 105808), APC anti-mouse CD11b/Mac-1 (101212, Biolegend), PE-Cy7 anti-mouse Ly-6G/Gr-1 (108416, Biolegend), PE-Cy7 anti-mouse Ly-6A/E/Sca-1 (108114, Biolegend), PerCP/ Cy5.5 anti-mouse CD45.2 (109828, Biolegend), PE/Cy7 anti-mouse CD117/cKit (105814, Biolegend), APC anti-mouse CD150 (115925, Biolegend), PE-Cy7 anti-human CD11B/MAC-1 (101215, Biolegend) and APC anti-human CD36 (336207, Biolegend). Pooled shRNAmir screening. An shRNA library targeting 626 chromatinassociated mouse genes (Supplementary Information; shRNAs prim. screen performance) was assembled in pLMN 15 by combining an existing chromatin-focused library (243 genes, 1094 shRNAs) 1 and 1793 additional shRNAs that were designed based on optimized sensor rules 32, 33 , and cloned, sequence-verified and pooled as previously described 1 . After spiking in several control shRNAs at equimolar ratios, the final pool of 2917 pLMN-shRNAs was transduced in triplicate into the same MLL-AF9;Nras G12D -driven model that we had previously used to identify BRD4 as a target in AML 1 . To ensure library representation a total of 60 million cells were infected with 5% transduction efficiency using conditions that predominantly lead to a single retroviral integration and represent each shRNA in a calculated number of . 800 cells. Throughout G418 drug selection (1 mg ml 21 ) more than 50 million cells were maintained at each passage to preserve library representation. Two days after infection T0 samples were acquired (6 million GFP 1 cells per replicate) using a FACS AriaII (BD Biosciences) and deep-sequencing analysis confirmed that the library was well represented in all replicates. After G418 drug selection for 7 days, T1 samples were obtained using FACS (6 million GFP 1 cells per replicate), and cells were subsequently cultured in the presence of 0.5 mg ml 21 G418 (15 million cells per replicate were maintained at each passage). To control for unspecific clonal events during the JQ1 resistance screen, stably selected cells were mixed in 4:1 ratio with G418-selected cells expressing an empty miR-30 cassette, mCherry and NeoR (pMSCVmiR30.empty-PGK-NeoR-IRES-mCherry). Replicates were subsequently treated for 4 days with 100 nM JQ1 followed by 50 nM JQ1 for 22 days. Culture medium was exchanged every 2 days until cells proliferated comparable to wild-type cells and afterwards passaged seven times. Three replicates cultured in the presence of vehicle (0.033% DMSO) were maintained in parallel. After 22 days (T2), about 6 million shRNA-expressing (GFP 1 ) cells were sorted for each replicate by FACS. While mCherry 1 cells completely disappeared over time, GFP 1 cells survived and eventually grew in the presence of 50 nM JQ1 (corresponding to an IC 70 dose in this model), indicating that resistance did not emerge from random clonal events, but from shRNA-mediated effects. Genomic DNA from T1 and T2 samples was isolated by two rounds of phenol extraction using PhaseLock tubes (5PRIME), followed by isopropanol precipitation. Deep-sequencing libraries were generated by PCR amplification of shRNA guide strands using primers that tag the product with standard Illumina adapters (p71Loop: CAAGCAGAAGACGGCATACGATAGTGAAGC CACAGATGT; p51PGK: AATGATACGGCGACCACCGATGGATGTGGAAT GTGTGCGAGG). For each sample, DNA from at least 5 3 10 6 cells was used as template in multiple parallel 50-ml PCR reactions, each containing 0.5 mg template, 13 AmpliTaq Gold buffer, 0.2 mM of each dNTP, 2 mM MgCl 2 , 0.3 mM of each primer and 2.5 U AmpliTaq Gold (Life Technologies), which were run using the following cycling parameters: 95 uC for 10 min; 35 cycles of 95 uC for 30 s, 52 uC for 45 s and 72 uC for 60 s; 72 uC for 7 min. PCR products (340 bp) were combined for each sample, column purified using the QIAquick PCR purification kit (Qiagen) and further purified on a 1% agarose gel (QIAquick gel extraction kit, Qiagen). Libraries were analysed on an Illumina HiSeq 2000 deep sequencer; 22 nucleotides of the guide strand were sequenced using a custom primer (miR30EcoRISeq, TAGCCCCTT GAATTCCGAGGCAGTAGGCA). To provide a sufficient baseline for detecting shRNA depletion in experimental samples, we aimed to acquire .500 reads per shRNA in the sequenced shRNA pool to compensate for variation in shRNA representation inherent in the pooled plasmid preparation or introduced by PCR biases. With these conditions, we acquired baselines of . 500 reads for all 2,917 shRNAs. Sequence processing was performed using a customized Galaxy platform 34 . For each shRNA and condition, the number of matching reads was normalized to the total number of library-specific reads per lane and imported into a database for further analysis (Access 2013, Microsoft). All primary screen data are provided under Supplementary Information; shRNAs prim. screen performance. Cell culture, retroviral gene transfer and RNAi studies. Mouse MLL-AF9;Nras G12D AML cells (RN2) 1 and other murine leukaemia cell lines were derived from bone marrow of terminally diseased mice transplanted with fetal liver cells engineered to express the indicated oncogenes, as previously described 35 . Murine leukaemia cells were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% FBS, 20 mM glutamate, 10 mM sodium pyruvate, 10 mM HEPES (pH 7.3), 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. MV4-11, MEG-01 and K-562 cells were grown in IMDM with 10% FBS, 20 mM glutamate, 10 mM sodium pyruvate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. All human AML cell lines were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% FBS, 20 mM glutamate, 10 mM sodium pyruvate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin, except KASUMI-1 cells, which were cultured in 20% FBS. Human PDAC cell lines CAPAN-2 and MIAPACA-2 were cultured in DMEM (GibcoInvitrogen) supplemented with 10% FBS, 20 mM glutamate, 10 mM sodium pyruvate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. SU-8686 and ASPC-1 were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% FBS, 20 mM glutamate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. HUPT-4 and HPAF-2 were cultured in EMEM (Sigma-Aldrich) supplemented with 10% FBS, 20 mM glutamate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. Human SCLC cell lines DMS-273, SHP-77, NCI-H82 and NCI-H1048 were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% FBS, 20 mM glutamate, 10% GlutaMAX, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. Cell lines were obtained from ATCC (http://www.lgcstandards-atcc.org/en.aspx) or DSMZ (http://www.dsmz.de/) and tested for mycoplasma infection on a regular basis using a commercial biochemical test (Lonza).
Tet-on competent murine pancreatic cancer cells (KRPC2) were generated and characterized as previously described 36 . In brief, pancreatic progenitor cells isolated from a murine fetus (ED17.5-18.5) harbouring a conditional endogenous Kras G12D allele (lox-STOP-lox-Kras G12D ) 37 and a conditional Trp53 deletion (Trp53 fl/fl ) 38 were transduced with retroviral constructs expressing Myc, 4-OHTinducible CreER T2 , codon-optimized Firefly Luciferase (Luc2), and rtTA3, and orthotopically injected into the pancreas of syngeneic recipient mice (detailed protocols available upon request). Emerging tumours were characterized to harbour histological features of human pancreatic adenocarcinoma and used to derive a cell line (KRPC2), which was cultured in DMEM (Gibco-Invitrogen) with 10% FBS, 20 mM glutamate, 10 mM sodium pyruvate, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. Retroviral packaging was performed using Platinium-E cells (Cell Biolabs) according to established protocols 11 . In brief, for each calcium phosphate transfection, 10-20 mg plasmid DNA and 5 mg helper plasmid (pCMV-Gag-Pol, Cell Biolabs) were used. Transduction efficiencies of retroviral constructs were measured 48 h post infection by flow cytometry (Guava easyCyte, Millipore). Transduced cell populations were usually selected 48 h post infection using 0.5 mg ml 21 G418 (Gibco, Life Technologies). To generate resistant MLL-AF9;Nras G12D murine leukaemia, cells were transduced with retrovirally delivered shRNAs or cDNAs at a transduction efficacy between 5-15% (predominantly yielding single viral integrations per cell). JQ1 treatment was started post infection and medium was carefully exchanged every 2 days to maintain a 50 nM JQ1 concentration until cells were proliferating normally and daily passaging was required. The starting point of JQ1 treatment is critical and can vary between different targets and shRNAs since the effect is dependent on shRNA potency, protein half-life of the respective target and the half-life of the associated chromatin mark. In case of strong detrimental effects the optimal start of JQ1 treatment needs to be determined for every target.
MOLM-13 and K-562 cells were modified to express the ecotropic receptor and rtTA3 using retroviral transduction of pMSCV-RIEP (pMSCV-rtTA3-IRESEcoR-PGK-Puro) or lentiviral transduction of pWPXLd-RIEP (pWPXLdrtTA3-IRES-EcoR-PGK-Puro) followed by puromycin selection (0.5 and 1 mg ml 21 , respectively, for 1 week). Derived cell lines were subsequently transduced with ecotropically packaged retroviruses.
For flow cytometry immunophenotyping, cultured cells were collected and stained using the indicated antibodies (two million cells in 100 ml FACS buffer:
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PBS, 5% FCS, 0.005% sodium acetate, and human or mouse TruStain fcX Fcreceptor blocking agent (Biolegend) for 20 min at 4 uC. Antibodies were diluted 1:400. Stained samples were analysed on an LSR Fortessa (BD) flow cytometer. Data analysis was performed using FlowJo software (Treestar). Cell viability assays for drug IC 50 and GI 50 determination were performed using Alamar blue staining according to manufacturer's guidelines, or by counting the increase in viable cell numbers over 72 h in the presence of different JQ1 concentrations. Dead cells were excluded using propidium iodide (PI) staining. Measurements of cell concentration were performed on a Guava easyCyte (Millipore), gating only viable cells (FSC/SSC/PI 2 ). Synergy was evaluated using Chou-Talalay Combination Index (CI), calculated with the CompuSyn program (ComboSyn, Inc.) 39 .
GI 50 values for all tested cell lines are provided in Supplementary Information; JQ1 profiled cell lines.
Competitive proliferation assays using shRNAs in pLMN, pLENC, pLMP or pRT3GEN-mir30/RT3GEN vectors were performed as described previously 1, 40 . Briefly, for assays involving Tet-regulated shRNA expression vectors, Tet-on competent MLL-AF9;Nras G12D mouse AML cells 40 or Tet-on competent derivatives of human leukaemia cell lines were transduced with the respective plasmid at infection rates of ,5% to ensure single-copy integration. For constitutive shRNA expression (pLMN) cells were analysed for GFP 1 expression 1 day post infection. pRT3GEN transduced cells were selected for 7 days using G418 (0.5 mg ml 21 ), mixed with 10% uninfected cells, and shRNA expression was induced through addition of doxycycline (DOX) to a final concentration of 1 mg ml
21
. The percentage of shRNA-expressing cells (turboGFP 1 or GFP 1 ) was measured daily using flow cytometry. All values were normalized to day 1. Once the percentage of viable cells was below 20%, measurements were discontinued (indicated in the graph by the discontinuation of the respective sample). Sequences for all shRNAs used in single assays are provided in Supplementary Information; shRNAs single assays.
Colony-forming assays were performed in Methocult (StemCell Technologies, Cat. No. M3231). 1000 AML cells (in 100 ml standard medium) were added to 900 ml Methocult supplemented with 1 ml of DMSO or JQ1 (to a final concentration of 200 nM). After 7 days the types of colonies were enumerated and normalized to input. Gene expression and protein level analysis. RNA was prepared using the RNeasy Plus Mini Kit (Qiagen). Synthesis of cDNA was performed using SuperScript III Reverse Transcriptase (Invitrogen) or Taqman reverse transcription kit (Applied Biosystems) with random hexamers. Quantitative PCR analysis was performed on an ABI 7900HT with SYBR green (ABI). All signals were quantified using the DC T method and were normalized to the levels of b-actin or GAPDH. All primers used in this study are presented in Supplementary Information; Primer.
For immunoblotting of Suz12, histone H3K27me3, BRD4, TCF4, IGF2BP1 and MYC, 20 mg of whole-cell lysate (lysis buffer: 50 mM TRIS pH 8, 250 mM NaCl, 0.5% NP-40, 5 mM EDTA) were loaded onto each lane. Protein extracts were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose for blotting. Preparation of RNA-seq libraries. RNA from human cell lines or mouse AML cells was isolated using the RNeasy Plus Mini Kit (Qiagen). Messenger RNA was obtained using two rounds of poly(A) selection using the Dynabeads mRNA purification kit (Invitrogen) and subsequently fragmented by incubation at 94 uC for 3 min (fragmentation buffer: 40 mM Tris base adjusted to pH 8.2 with glacial acetic acid, 100 mM potassium acetate, 30 mM magnesium acetate in DEPC-treated H 2 O). Cell lines infected with shRNA expressing vectors were FAC-sorted for shRNA expression (GFP 1 ) before RNA extraction. The fragmented mRNA was used as template for first-strand cDNA synthesis with random hexamers and a NEBNext DNA Library Prep Master Mix Set for Illumina Synthesis kit (Invitrogen). The second-strand cDNA was synthesized with 100 mM dATP, dCTP, dGTP and dUTP in the presence of RNase H, E. coli DNA polymerase I and DNA ligase (Invitrogen). The incorporation of dUTP allowed elimination of the second strand during library preparation (described below) and thus preservation of strand specificity. Chromatin immunoprecipitation and ChIP-seq library construction. ChIP assays were performed exactly as described 14 in two to three independent biological replicates. Crosslinking was performed with sequential EGS and formaldehyde or with formaldehyde alone. All samples were quantified by quantitative PCR performed using SYBR green (ABI) on an ABI 7900HT after crosslink reversal. Each immunoprecipitate signal was referenced to an input standard-curve dilution series (immunoprecipitate/input) to normalize for differences in starting cell number and for primer amplification efficiency and normalized to a control region. Two independent biological replicates were performed for each ChIPseq experiment.
For ChIP-Seq library construction, 1 3 10 7 leukaemia cells were crosslinked using 1% formaldehyde for 20 min at room temperature. After purifying immunoprecipitated DNA using QIAquick Gel Extraction Kit (QIAGEN), ChIP-seq libraries were constructed using the TruSeq ChIP Sample Prep Kit (illumina) following manufacturer's instructions with the following exception: following adaptor ligation, libraries were amplified for 15 cycles. In brief, purified ChIP DNA was repaired to blunt ends followed by dA-tailing process to ligate adapters for multiplex-based sequencing. Size-selection of adaptor-ligated ChIP-DNA was performed with agarose-gel-based selection of DNA size ranged from 200 to 350 bp. The final libraries were amplified for 15 cycles, and size-selected with SPRI clean-up by using AMPure XP beads (Beckman Coulter). Library quality was determined using a Bioanalyzer (Agilent). Libraries sizes ranged from 250 to 300 bp. ChIP-seq libraries were sequenced using an Illumina HiSeq 2000 platform. Barcoded libraries were sequenced in a multiplexed fashion with two to six libraries at equal molar ratio, with single-end reads of 50 bases. Illumina deep sequencing. Two to five nanograms of cDNA or DNA precipitated by ChIP was used as starting material for the generation of single-end sequencing libraries as described in Illumina's ChIP-seq sample preparation protocol. DNA fragments of the following sizes were selected for these experiments: 200-350 bp for ChIP-seq, 150-700 bp for RNA-seq. For strand-specific RNA-seq, the uridine residues present in one cDNA strand were digested with uracil-N-glycosylase (New England Biolabs), followed by PCR amplification. Completed libraries were quantified on a Bioanalyzer using the dsDNA 1000 assay kit (Agilent) and the qPCR NGS library quantification kit (Agilent). Cluster generation and sequencing was performed using a HiSeq 2000 system with a read length of 50 or 100 nucleotides according to the manufacturer's guidelines (Illumina). Analysis of RNA-seq data. The calculation of RNA expression values was based on the RefSeq database, which was downloaded from UCSC on 10 January 2014. Genes with overlapping exons were flagged and double entries (that is, exactly the same gene at two different genomic locations) were renamed. Identical genes with more than one assigned gene symbol were flagged. Genes with several transcripts were merged to consensus genes consisting of a union of all underlying exons using the fuge software (I. Tamir, unpublished), which resulted in 25,098 gene models. Gene names and accession numbers of identical genes are presented in Supplementary Information; refseq.hg19.2014_0110.imp.map.
Paired-end and single-read fragments were trimmed on their 59 end (six cycles PE100, two cycles SR50 NEB RNA sample prep protocol), adaptors were removed using cutadapt v1.4.2 41 and reads with a length of less than 18 bp in any read of the pair were discarded. The trimmed and adaptor-free reads were aligned against rDNA of the respective organism using bowtie2 v2.0.2 42 for paired-end and bowtie v0.12.5 43 for single-end reads. The rRNA cleaned paired-end reads were aligned against the transcriptome to estimate the fragment size and the standard deviation of the fragment size using bwa v0.6.2 44 . The rRNA cleaned reads were aligned to the genome with the TopHat splice junction mapper for RNA-seq reads 45 . The uniquely aligning reads were used for counting per gene with htseq-count v0.6.1p 46 with the overlap-resolution mode option set to 'union' using the processed RefSeqannotated gene database. Reads per kilobase per million mapped reads (RPKM) values for all samples were calculated as in ref. 47 . Read counts for all samples were normalized using the median-of-ratios method implemented in DESeq2, v1.2.10 48 . Counts were transformed for PCA using DESeq2's variance stabilizing transformation. For both the resistant and sensitive groups, three independent RNA-seq experiments on different leukaemia cell lines were available. The edgeR R package v3.4.2 49 was used to calculate the significance of difference in expression of resistant and sensitive leukaemia cell lines (DMSO treated) in Fig. 4a . For this, raw counts were normalized using the 'relative log expression' method analogous to DESeq2. Dispersions were sequentially estimated with the default settings by first estimating a common dispersion for the gene set and then 'shrinking' tag-wise dispersion values towards that dispersion trend. Statistical modelling and analysis was done by fitting a model taking the separation into sensitive and resistant cell lines into account. Differential expression of genes between those two groups was subjected to statistical analysis and resulting P values were adjusted for multiple testing with the Benjamini-Hochberg correction 50 . The resulting list was further filtered by only considering genes which all have higher normalized counts in the sensitive cell lines versus the resistant cell lines or vice versa. Gene set enrichment analysis. Gene set enrichment analysis 20 was performed using GSEA v2.07 software with 1,000 gene set permutations. KEGG signalling gene sets and Wnt signalling associated gene sets were obtained from the Molecular Signatures Database v4.0 (MSigDB, http://www.broadinstitute.org/ gsea/msigdb/index.jsp). To perform GSEA with human gene signatures, human-mouse homologues from the mouse gene sets were identified and converted into human gene names using the NCBI homologene database (build68). Ambiguous homologue mapping, that is, different mouse gene names pointing to the same human homologue, was excluded. A detailed description of GSEA methodology and interpretation is provided at http://www.broadinstitute.org/gsea/doc/ GSEAUserGuideFrame.html. In brief, the normalized enrichment score (NES) provides "the degree to which a gene set is overrepresented at the top or bottom LETTER RESEARCH of a ranked list of genes". The nominal P value (Nom p-val) describes "the statistical significance of the enrichment score". The false discovery rate q value (FDR q-val) is "the estimated probability that a gene set with a given NES represents a false positive finding". In general, given the lack of coherence in most expression data sets and the relatively small number of gene sets being analysed, an FDR cut-off of 25% is appropriate. All gene sets used in this study are provided in Supplementary Information; GSEA gene sets. ChIP-seq data analysis. Adaptors of the single-read fragments were removed using cutadapt v1.4.2 41 and reads with a length of less than 18bp in any read of the pair were discarded. The remaining reads were aligned to the genome (mouse: mm10, human: hg19) using Bowtie v1.0.0 43 . Reads with same start and end position on the same strand were removed from the alignment. To identify ChIP-seq peaks, we used the MACS2 v2.1.0.20141030 (https://github.com/taoliu/MACS/) peak finding algorithm. A threefold enrichment relative to input control samples was used for peak calling as well as the option to call broad peaks. Building a shifting model was disabled and the small nearby and large nearby region parameters were set to 5,000 and 20,000 respectively. The extension size was set to the respective median insert size of the ChIP-seq treatment sample for paired-end data and the estimated fragment size for single-end data. Read numbers for the resulting peaks were quantified using the BEDTools suite 51 and normalized to total mapped reads. The Brd4 ChIP-seq track was obtained from published data sets 19 (GEO sample GSM1262345). Peaks were assigned to modified versions of the RefSeq database (GRCh37/hg19 downloaded on 10 January 2014 from UCSC Table Browser and GRCm38/mm10 downloaded on 30 June 2014 from UCSC Table Browser) by assigning peaks to the closest upstream/downstream TSS using BEDTools. For these versions, overlapping genes were flagged and double entries (that is, exactly the same gene at two different genomic locations) were renamed. Identical genes with more than one assigned gene symbol were flagged. For the density heat maps, ChIP-seq peaks were identified using the MACS version 1.4.0beta (Model based Analysis of ChIP-Seq) peak finding algorithm 52 . A P value threshold of enrichment of 1 310 25 , a false discovery rate (FDR) of less than 1%, and a fivefold enrichment relative to input control samples were used for all peak calling. The Brd4 peaks were considered as promoter if the peak showed at least 1 bp overlap within 6200 bp of RefSeq gene TSSs. If Brd4-called peaks showed no overlap within 6200 bp of RefSeq gene TSSs, they were considered as enhancerbound peaks. Heat map matrices were created by counting tags using a 10 kb window (65 kb of the peak summit) and 20 bp bin size. Further visualization of heat map matrices were done using Java TreeView 1.1.6r4 (http://jtreeview.sourceforge.net). For comparing DMSO and JQ1 treated ChIP-seq data sets, heat map matrices were normalized to total mapped reads counts before visualization with Java TreeView. STARR-seq screens. STARR-seq screens were done as described previously 24 , with the following exceptions. DNA from 21 bacterial artificial chromosomes (BACs), which were available for the extended MYC locus covering approximately 91% of the surrounding 3 Mb of the genomic region, plus 25 genic control BACs, were used for library generation. The fragmented BAC DNA was cloned into the human STARR-seq screening vector 24 containing a minimal MYC promoter. We transfected 500 mg of this library into 1 3 10 8 K-562 cells per condition, using a BTX Agile Pulse MAX system (Harvard Apparatus) following the manufacturer's protocol. Electroporation conditions: two pulses at 750 V for 0.5 ms (100 ms interval), followed by 5 pulses of 250 V for 2 ms (100 ms interval) in BTXpress cytoporation medium T. After electroporation, the cells were grown at 37 uC in RPMI-1640 containing either DMSO or 250 nM JQ1 and were harvested after 24 h. For each screen we isolated poly(A) RNA and processed it as described before 24 , with a different extension time of 45 s in the final amplification of the cDNA and modified primers for the first cDNA amplification. All BACs used for the STARR-seq screen are provided in Supplementary Information; STARR-seq BACs. STARR-seq deep sequencing and analysis. All sequencing was performed as a 50-cycle paired-end run on an Illumina HiSeq2000 machine. STARR-seq and input read processing was performed as described 24 , with the following exceptions. Libraries from different conditions were normalized to each other by subsampling to 10 5 reads per condition using reservoir sampling. Peaks were called using macs2 (v2.1.0) 52 with the input library as background. The peaks were then filtered for a minimal fold enrichment of three and only peaks with at least five reads per kb were considered for further analysis. Peak calling was performed for STARR-seq reads from both conditions (DMSO and JQ1) and the resulting peaks were merged using bedtools merge 51 . STARR-seq enrichment was calculated using bedtools coverage 51 . Differential fold enrichment was calculated as the ratio between enrichments in JQ1 over DMSO and expressed in log 2 . Luciferase assays and data analysis. Luciferase assays were done as described previously 24 , with the following exceptions. Enhancer candidate regions were amplified from genomic DNA and shuttled into a modified pGL4 luciferase reporter vector containing a minimal MYC promoter (chr8:128,748,440-128,748,550). Each construct was tested by co-transfecting 10 6 K-562 cells with 45 mg of the firefly luciferase construct and 5 mg of a renilla luciferase control plasmid (pGL4.75, Promega). After electroporation, the cells were grown at 37 uC in RPMI-1640 containing either DMSO or 250 nM JQ1 and were harvested after 46 h. Relative luciferase signals (firefly/renilla) were normalized to signal from two negative background sequences chosen based on their absence of STARR-seq signal and expressed as fold change over background. We analysed the statistical significance of differential luciferase signals with or without JQ1 treatment using an unpaired t-test with Welch's correction for three biological replicates. Primer sequences which were used to amplify the particular enhancer regions are deposited in Supplementary Information; Primer. Animal experiments. Mouse MLL-AF9;Nras G12D leukaemia cells (RN2) were transplanted by tail-vein injection of 1 3 10 5 cells into sub-lethally (5.5 Gy) irradiated female B6/SJL (CD45.1) recipient mice at the age of 6-10 weeks (n 5 5, for each individual experiment). For whole-body bioluminescent imaging, mice were intraperitoneally injected with 50 mg kg 21 D-luciferin (Goldbio), and after 5 min were analysed using an IVIS Spectrum system (Caliper LifeSciences). For JQ1 treatment trials, a stock of 100 mg ml 21 JQ1 in DMSO was 20-fold diluted by dropwise addition of a 10% 2-hydroxypropyl-b-cyclodextrin carrier (Sigma) under vortexing, yielding a 5 mg ml 21 final solution. Mice were intraperitoneally injected daily with freshly diluted JQ1 (50 mg kg 21 ) or a similar volume of carrier containing 5% DMSO. JQ1 treatment was started 3 days after transplantation of RN2 cells stably transduced with pLMN shRen.713 and shSuz12.1676. Mice transplanted with RN2 cells expressing b-catenin cDNA or empty vector were treated with JQ1 daily starting 1 day after transplantation. All animals were maintained in the pathogen-free animal facility of the Research Institute of Molecular Pathology, and all procedures were carried out according to an ethical animal license, which is approved and regularly controlled by the Austrian Veterinary Authorities. No statistical methods were used to predetermine sample size. The investigators were not blinded to allocation during experiments and outcome assessment. Randomization was not applied because all animals used in this study were similar for age, sex and strain background. Patient sample analysis. Ten patients with AML (females, n 5 4; males, n 5 6) and two with CML blast phase (BP) (males, n 5 2) were examined. Diagnoses were established according to the proposal of the French-American-British (FAB) cooperative study group 53, 54 and the classification of the World Health Organization (WHO) 55 . Informed consent was obtained before bone marrow puncture in each case. The study was approved by the Institutional Review Board (Ethics Committee) of the Medical University of Vienna. Mononuclear cells (MNC) were isolated using Ficoll and stored in liquid nitrogen until used. After thawing, the viability of cells ranged from 75% to 85% as assessed by trypan blue exclusion. RNA was isolated from bone marrow or peripheral blood MNC using the RNeasy MinElute CleanupKit (Qiagen). cDNA was synthesized using RQ1 DNase buffer, RQ1 DNase and RQ1 DNase Stop Solution (Promega), Moloney murine leukaemia virus reverse transcriptase, random primers, First Strand buffer, dNTPs (100 mM), and RNasin (Invitrogen) according to the manufacturer's instructions. Details of the patient material used is deposited in Supplementary Information; Patient information.
MNC were cultured in 96-well plates (TPP) in RPMI-1640 medium (Lonza) with 10% fetal calf serum in the absence or presence of JQ1 (50-5,000 nM) at 37 uC for 48 h. AML MNC were incubated with JQ1 in the presence of 100 ng ml 21 recombinant human (rh) G-CSF (Amgen), 100 ng ml 21 rhSCF (Peprotech) and 100 ng ml 21 rhIL-3 (Novartis Pharma AG). CML BP cells were incubated with JQ1 without cytokines. After incubation, 0.5 mCi 3H-thymidine (Perkin Elmer) was added for 16 h. Cells were then harvested on filter membranes in a Filtermate 196 harvester (Packard Bioscience). Filters were air-dried and the bound radioactivity was measured in a Top-Count NXT b-counter (Packard Bioscience). All experiments were performed in triplicates. Proliferation was calculated as a percentage of medium control, and the inhibitory effects of JQ1 were expressed as IC 50 values. Statistical analyses. Results are expressed as means 6 standard error of the mean. If not stated otherwise statistical significance was calculated by two-tailed unpaired t-test on two experimental conditions with P , 0.05 considered statistically significant. Statistical significance levels are denoted as follows: ****P , 0.0001; ***P , 0.001; **P , 0.01; *P , 0.05. No statistical methods were used to predetermine sample size. . Positive control shRNAs targeting essential genes are marked in red; negative control shRNAs are depicted in green. c, Scatter plot depicting all genes ranked by the sum of their average depletion score of all shRNAs across all three replicates. Top scoring hits were defined as genes for which at least two shRNAs showed an average depletion of eightfold after 7 days of shRNA expression and are marked in red (45 genes). d, IC 50 determination for JQ1 in murine MLL-AF9;Nras G12D AML cells (RN2). Obtained numbers of viable cells per ml were normalized to DMSO (n 5 3, mean 6 s.e.m.). e, Table showing (pRT3GEN-miR30) . Transduced cells were selected with G418 and subsequently mixed with wild-type (wt) cells in a ratio of 95% to 5%. shRNA-expression was induced using dox treatment (1 mg ml
; from day 0), and the fraction of GFP 1 cells was measured over time and plotted relative to day 2. JQ1 treatment (50 nM) was initiated in one of the duplicate samples at the indicated time point (red arrow). Once the percentage of viable cells was below 10%, measurements were discontinued (indicated in the graph by the discontinuation of the respective sample). The negative effect induced by Suz12 suppression is reverted upon treatment with JQ1, which is not the case when Myc is suppressed. d, Bar chart showing colony-forming cell frequencies of MLL-AF9;Nras G12D leukaemia cells expressing Ren.713 or Suz12.1676 shRNAs in the presence of DMSO or 200 nM JQ1; type 1, myeloblasts; type 2, maturing myeloblasts; type 3, terminally differentiated myeloid cells (n 5 3, mean 6 s.e.m.). e, Pie charts depicting the fraction of JQ1-response genes which are re-expressed to the indicated extent in mouse resistant AML cells expressing shRNAs targeting Dnmt3a and Psip1 (continuation of Fig. 2b) . JQ1-response genes (Fig. 2a) were grouped into four categories based on the divergence of their expression in resistant AML compared to AML expressing Ren.713 (not changed compared to expression after 24 h JQ1, less than 1.5-fold; restoration relative to DMSO control: full restoration, less than 1.5-fold; enhanced, above 1.5-fold; partial restoration, restored but less than 1.5 fold) f, Heat map showing the distribution of H3K27me3, H3K36me3 and H3K4me3 ChIP-seq peaks (fold enrichment .5 over input, FDR ,1%) relative to Brd4 enhancer and promoter binding sites in MLL-AF9;Nras G12D AML cells with and without JQ1 treatment. g, ChIP-seq occupancy profiles of Brd4 and H3K27me3 and H3K36me3 chromatin marks at enhancer regions downstream of Myc and upstream of Tifab following 3 days of treatment with vehicle or JQ1 (25 nM). y axis reflects the number of normalized cumulative tag counts in each region. E2F5  BMPR2  SMAD9  ZFYVE16  PPP2R1B  CDKN2B  ACVR2A  ROCK2  THBS1  MAPK1  ID2  SMURF2  SMAD4  SKP1  ACVR2B KEGG_TGF-BETA_Signaling NFATC2  PRKX  CTNNBIP1  NFATC1  FZD2  PPP2R1B  CCND2  PRKACA  PRKCA  WNT5B  CSNK2A1  CTNNB1  SENP2  DKK2  ROCK2  CAMK2G  SIAH1  FZD4  SMAD4  SKP1  PRKCB  PPP3R1  TBL1X  GSK3B  PRICKLE1  CSNK1A1  MAPK9  CACYBP  WNT9B  LRP6  WNT10A  CAMK2A  PPP2R5E  RAC1  ROCK1  WNT2B Leukemia (22) Myeloma (13) Bladder (11) Brain (13) Breast (17) Cervix (7) Colon (27) Kidney (9) Liver (6) NSCLC (15) SCLC (13) Melanoma (16) Neuroblastoma (7) Pancreas (12) Prostate (6) Sarcoma (18) Stomach (8) 10,000 Plotted is the relative fraction of GFP 1 cells 72 h after JQ1 treatment using the indicated doses (n 5 3, means 6 s.e.m., ***P , 0.001; **P , 0.01; *P , 0.05 as determined by Student's t-test). Cells overexpressing TCF4 exhibit a dosedependent competitive advantage under JQ1 treatment. c, Protein levels of TCF4 after overexpression of TCF4 cDNA subcloned into pMSCV-PGKNeoR-IRES-GFP in MOLM-13 after 4 weeks of G418 (0.5 mg ml Extended Data Figure 9 | Wnt signatures are generally associated with BET resistance and Wnt activation drives resistance of pancreatic cancer models. The BETi_Resistance_Rathert signature was defined by combining the core enriched genes from the two significant Wnt gene sets (KEGG_WNT_ SIGNALING and ST_WNT_SIGNALING) in murine resistant AML, filtered for significant upregulation (DESeq padj ,0.1). These were combined with the Wnt-associated genes found differentially expressed in resistant human leukaemia cell lines and primary patient samples, resulting in a total of 26 genes. a, Left, microarray expression data of all 26 signature genes was curated from the Cancer Cell Line Encyclopedia (CCLE) 28 and normalized to the geometric mean of each individual gene throughout all samples (relative expression). The sum of the relative expression of all genes (resistance index) was plotted for all CCLE cell lines showing a GI 50 . 450 nM (resistant, 54 total) or a GI 50 , 150 nM (sensitive, 55 total) based on our sensitivity profiling (statistical significance was determined using Student's t-test). Right, gene set enrichment analysis plot comparing the expression of 26 signature genes associated with JQ1 resistance across 54 resistant (GI 50 . 450 nM) and 55 sensitive cell lines (GI 50 , 150 nM) available from CCLE. b, Left, as in a the resistance index was calculated as the sum of relative expression values of all 26 signature genes, which were based on RPKM extracted from an independent RNA-seq data set 27 . Plotted are all 49 resistant (GI 50 . 450 nM) and all 50 sensitive (GI 50 , 150 nM) cell lines analysed in both sensitivity profiling and RNA-seq 27 (statistical significance determined using Student's t-test). Right, gene set enrichment analysis plot comparing the expression of 26 signature genes associated with JQ1 resistance across 49 resistant (GI 50 . 450 nM) and 50 sensitive cell lines (GI 50 , 150 nM) available from ref. 27 . c, Competitive proliferation assays of murine pancreatic adenocarcinoma (KRPC2) cells transduced with pLEPC constructs expressing potent validated shRNAs targeting Apc, cultured in the presence of JQ1 (800 nM) or DMSO. Shown is the relative number of mCherry 1 cells over time, relative to initial. d, Cell viability of murine KRPC2 was determined following 5 days of treatment with pyrvinium and/or JQ1 as indicated (n 5 3, mean 6 s.e.m., statistical significance determined using Student's t-test). The combination index (CI) for drug combinations was calculated using the CompuSyn software and percentage inhibition (fraction affected, Fa) resulting from combined action of the two drugs versus effects of either drug alone. CI values ,1.0 indicate synergism of the two agents. e, As in d, cell viability was determined for human ASPC-1 pancreatic cancer cells following 5 days of treatment with pyrvinium and/or JQ1 as indicated (n 5 3, mean 6 s.e.m., statistical significance determined using Student's t-test). The combination index for drug combinations was obtained using percentage inhibition (fraction affected, Fa) resulting from combined action of the two drugs versus effects of either drug alone. primary AML patient samples. a, Determination of JQ1 response profiles in 12 primary AML patient samples. Sensitivity was determined using 3H-thymidine uptake across different JQ1 concentrations. b, qRT-PCR analysis of mRNA levels of additional Wnt-associated genes in primary human leukaemia samples relative to GAPDH (continuation of Fig. 4g ). Patient groups with low JQ1 IC 50 (,200 nM, blue dots) were compared to patients with high IC 50 (.500 nM, red dots). Statistical significance was determined using a Student's t-test. c, Definition of a JQ1 resistance index. Expression of HOXB4, TCF4 and CCND2 in each primary AML patient sample was normalized to the geometric mean of all samples. The sum of these relative expression values of all three genes were added up to a resistance index, which was plotted in comparison to the JQ1 IC 50 of each sensitive (IC 50 , 200 nM, blue dots) and resistant (IC 50 . 500 nM, red dots) AML patient sample. Two-tailed Pearson correlation coefficient r and P value are shown.
RESEARCH LETTER

LETTER RESEARCH
